A study examined the clinical characteristics, disease burden, and treatment patterns among patients aged 65 years and older with recurrent pericarditis (RP). The findings were published as a poster at the Academy of Managed Care Pharmacy Nexus 2021.
“In older adults, RP disease and treatment management with conventional therapies (CTs) may be more challenging due to greater underlying comorbidities and iatrogenic drug effects. Additionally, few studies have described RP in this population,” the researchers wrote.
In this exploratory, retrospective analysis of claims, researchers analyzed 228 older patients with RP who had “idiopathic” pericarditis, via the Inovalon Ability claims database (2013-2020). RP recurrence was defined as a pericarditis claim occurring ≥28 days after a prior episode. To meet the inclusion criteria, RP qualifying events (QE) required at least two recurrences or one recurrence with a serious complication. The researchers assessed disease burden, treatment patterns, and RP-related outcomes.
Among the population of interest, the researchers observed multiple comorbidities, including chronic obstructive pulmonary disease (48%), diabetes (42%), and congestive heart failure (34%). The researchers observed an increase in the Charlson Comorbidity Index from 2.1 to 3.7 from the first pericarditis episode to a RP qualifying event, over an average of six months.
“Older RP patients exhibited substantial RP morbidity associated with a broad range of comorbidities. Substantially fewer older patients received CT than reported in the general RP population in this claims study, possibly due to of iatrogenic drug effects, which can be worse in older patients,” the researchers concluded. “The results indicate older RP patients may be undertreated, highlighting an unmet need for safe and effective RP treatments in this population.”
Source: Luis S, et al. Characterization of Recurrent Pericarditis in Medicare Advantage Patients: Disease Burden, Pharmacotherapy, and Outcomes. Poster I3. Published for AMCP Nexus 2021; October 18-21, 2021, Denver, CO.